The Experts below are selected from a list of 26199 Experts worldwide ranked by ideXlab platform

Jin Yong Sung - One of the best experts on this subject based on the ideXlab platform.

  • False Negative Rate of fine needle aspiration in thyroid nodules impact of nodule size and ultrasound pattern
    Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2019
    Co-Authors: Dong Gyu Na, Jung Hwan Baek, Jin Yong Sung
    Abstract:

    BACKGROUND: To retrospectively evaluate the False Negative Rate of ultrasound-guided fine needle aspiration (FNA) according to the nodule size and ultrasound pattern. METHODS: We included 432 consecutive thyroid nodules from 384 patients who underwent ultrasound-guided FNA with benign results (≥1 cm). The False Negative Rate in the nodules was assessed according to the nodule size and ultrasound pattern based on the Korean-Thyroid Imaging Reporting and Data System (K-TIRADS). RESULTS: The overall False Negative Rate was 3.2%. There was a trend toward an increasing False Negative Rate as the K-TIRADS score increased (P < .001). In low or high suspicion nodules (K-TIRADS 3 and 5), there was no significant difference in False Negative Rate according to the nodule size; however, among the intermediate suspicion nodules (K-TIRADS 4), the False Negative Rate was higher in large nodules (≥3 cm, P = .039). CONCLUSION: The impact of nodule size on the False Negative Rate differed according to the ultrasound pattern.

  • False Negative Rate of fine-needle aspiration in thyroid nodules: impact of nodule size and ultrasound pattern.
    Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2019
    Co-Authors: Dong Gyu Na, Jung Hwan Baek, Jin Yong Sung
    Abstract:

    BACKGROUND: To retrospectively evaluate the False Negative Rate of ultrasound-guided fine needle aspiration (FNA) according to the nodule size and ultrasound pattern. METHODS: We included 432 consecutive thyroid nodules from 384 patients who underwent ultrasound-guided FNA with benign results (≥1 cm). The False Negative Rate in the nodules was assessed according to the nodule size and ultrasound pattern based on the Korean-Thyroid Imaging Reporting and Data System (K-TIRADS). RESULTS: The overall False Negative Rate was 3.2%. There was a trend toward an increasing False Negative Rate as the K-TIRADS score increased (P 

Judy C Boughey - One of the best experts on this subject based on the ideXlab platform.

  • abstract es7 1 methods to minimize the False Negative Rate of sentinel lymph node surgery after neoadjuvant chemotherapy for node positive breast cancer
    Cancer Research, 2019
    Co-Authors: Judy C Boughey
    Abstract:

    Neoadjuvant chemotherapy (NAC) is known to decrease the extent of disease in the breast and increase Rates of breast conservation. In addition, NAC also can reduce the likelihood of nodal positivity and hence decrease need for axillary node dissection and its associated morbidities. Three prospective clinical trials have assessed the False Negative Rate (FNR) of SLN after NAC for patients with clinically node-positive disease at presentation. The American College of Surgeons Oncology Group (ACOSOG) Z1071 study reported a False Negative Rate (FNR) of SLN surgery of 12.6% in patients with cN1 disease with 2 or more SLNs resected. The FNR was lower at 10.6% when dual tracer technique was utilized. Additional analysis showed that when a clip was placed in the positive node at diagnosis and the clipped node was resected as one of the SLNs, the FNR was 6.8%. The Canadian study (SN FNAC - sentinel node following neoadjuvant chemotherapy) reported a FNR of 13.3% when defining SLN with isolated tumor cells (ITC) as Negative and 8.4% when including ITC in the definition of a positive SLN. The SENTINA study from Europe reported an overall FNR of 14.2%, however when excluding patients with only a single SLN removed the FNR was 9.8%. Further work with preoperative localization of the clipped node with a seed and resection of the localized clipped node along with the sentinel nodes (termed targeted axillary dissection) has been shown to have a FNR of 2.4%. Surgeons are incorporating SLN after NAC into their clinical practice for patients with a good response to NAC and thus use of SLN surgery after NAC for patients with node-positive breast cancer is increasing. There are multiple methods that can decrease the FNR of the procedure in this setting. These include use of dual tracer for SLN identification, resection of the initial biopsy-proven positive node, resection of at least 2 SLNs and use of immunohistochemical staining of the SLNs. There are several different techniques to assist with ensuring resection of the initially biopsy-proven positive lymph node which include varying methods to mark the node at diagnosis and ways to identify the node at time of SLN surgery. The node can be marked at the time of percutaneous lymph node biopsy (or at a subsequent visit prior to initiation of NAC) with a clip, a radioactive seed, or tattooed with ink. At the time of surgery, if ink or a radioactive seed was placed, the node can be identified using these techniques at the time of axillary surgery. If a clip was placed at diagnosis, this can undergo preoperative localization, with a radioactive seed or wire, to maximize likelihood of identifying the clipped node during surgery. For patients with biopsy-proven node-positive breast cancer, SLN surgery after NAC allows assessment of residual nodal disease and can enable patients who have their axillary disease eradicated by NAC to avoid ALND. Citation Format: Boughey J. Methods to minimize the False Negative Rate of sentinel lymph node surgery after neoadjuvant chemotherapy for node positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr ES7-1.

  • identification and resection of clipped node decreases the False Negative Rate of sentinel lymph node surgery in patients presenting with node positive breast cancer t0 t4 n1 n2 who receive neoadjuvant chemotherapy results from acosog z1071 alliance
    Annals of Surgery, 2016
    Co-Authors: Judy C Boughey, Karla V Ballman, Linda M Mccall, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, Huong Lepetross, Eric Feliberti, Kelly K Hunt
    Abstract:

    BACKGROUND: The American College of Surgeons Oncology Group Z1071 trial reported a False-Negative Rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-positive breast cancer. One proposed method to decrease the FNR is clip placement in the positive node at initial diagnosis with confirmation of clipped node resection at surgery. METHODS: Z1071 was a multi-institutional trial wherein women with clinical T0-T4,N1-N2,M0 breast cancer underwent SLN surgery and axillary dissection (ALND) after neoadjuvant chemotherapy. In cases with a clip placed in the node, the clip location at surgery (SLN or ALND) was evaluated. RESULTS: A clip was placed at initial node biopsy in 203 patients. In the 170 (83.7%) patients with cN1 disease and at least 2 SLNs resected, clip location was confirmed in 141 cases. In 107 (75.9%) patients where the clipped node was within the SLN specimen, the FNR was 6.8% (confidence interval [CI]: 1.9%-16.5%). In 34 (24.1%) cases where the clipped node was in the ALND specimen, the FNR was 19.0% (CI: 5.4%-41.9%). In cases without a clip placed (n = 355) and in those where clipped node location was not confirmed at surgery (n = 29), the FNR was 13.4% and 14.3%, respectively. CONCLUSIONS: Clip placement at diagnosis of node-positive disease with removal of the clipped node during SLN surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy. Clip placement in the biopsy-proven node at diagnosis and evaluation of resected specimens for the clipped node should be considered when conducting SLN surgery in this setting.

  • abstract p2 01 02 methods impacting the False Negative Rate of sentinel lymph node surgery in patients presenting with node positive breast cancer t0 t4 n1 2 who receive neoadjuvant chemotherapy results from a prospective trial acosog z1071 alliance
    Cancer Research, 2015
    Co-Authors: Judy C Boughey, Karla V Ballman, W F Symmans, Linda M Mccall, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, Kelly K Hunt
    Abstract:

    Background: The American College of Surgeons Oncology Group (ACOSOG) Z1071 trial (Alliance) reported a False Negative Rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-positive breast cancer. Proposed methods to decrease the FNR include clip placement in the positive node at initial diagnosis with confirmation of resection of the clipped node at surgery and inclusion of residual metastatic cells identified by immunohistochemistry (IHC) for cytokeratins and disease measuring

Kelly K Hunt - One of the best experts on this subject based on the ideXlab platform.

  • identification and resection of clipped node decreases the False Negative Rate of sentinel lymph node surgery in patients presenting with node positive breast cancer t0 t4 n1 n2 who receive neoadjuvant chemotherapy results from acosog z1071 alliance
    Annals of Surgery, 2016
    Co-Authors: Judy C Boughey, Karla V Ballman, Linda M Mccall, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, Huong Lepetross, Eric Feliberti, Kelly K Hunt
    Abstract:

    BACKGROUND: The American College of Surgeons Oncology Group Z1071 trial reported a False-Negative Rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-positive breast cancer. One proposed method to decrease the FNR is clip placement in the positive node at initial diagnosis with confirmation of clipped node resection at surgery. METHODS: Z1071 was a multi-institutional trial wherein women with clinical T0-T4,N1-N2,M0 breast cancer underwent SLN surgery and axillary dissection (ALND) after neoadjuvant chemotherapy. In cases with a clip placed in the node, the clip location at surgery (SLN or ALND) was evaluated. RESULTS: A clip was placed at initial node biopsy in 203 patients. In the 170 (83.7%) patients with cN1 disease and at least 2 SLNs resected, clip location was confirmed in 141 cases. In 107 (75.9%) patients where the clipped node was within the SLN specimen, the FNR was 6.8% (confidence interval [CI]: 1.9%-16.5%). In 34 (24.1%) cases where the clipped node was in the ALND specimen, the FNR was 19.0% (CI: 5.4%-41.9%). In cases without a clip placed (n = 355) and in those where clipped node location was not confirmed at surgery (n = 29), the FNR was 13.4% and 14.3%, respectively. CONCLUSIONS: Clip placement at diagnosis of node-positive disease with removal of the clipped node during SLN surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy. Clip placement in the biopsy-proven node at diagnosis and evaluation of resected specimens for the clipped node should be considered when conducting SLN surgery in this setting.

  • abstract p2 01 02 methods impacting the False Negative Rate of sentinel lymph node surgery in patients presenting with node positive breast cancer t0 t4 n1 2 who receive neoadjuvant chemotherapy results from a prospective trial acosog z1071 alliance
    Cancer Research, 2015
    Co-Authors: Judy C Boughey, Karla V Ballman, W F Symmans, Linda M Mccall, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, Kelly K Hunt
    Abstract:

    Background: The American College of Surgeons Oncology Group (ACOSOG) Z1071 trial (Alliance) reported a False Negative Rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-positive breast cancer. Proposed methods to decrease the FNR include clip placement in the positive node at initial diagnosis with confirmation of resection of the clipped node at surgery and inclusion of residual metastatic cells identified by immunohistochemistry (IHC) for cytokeratins and disease measuring

Halil Dincer - One of the best experts on this subject based on the ideXlab platform.

Dong Gyu Na - One of the best experts on this subject based on the ideXlab platform.

  • False Negative Rate of fine needle aspiration in thyroid nodules impact of nodule size and ultrasound pattern
    Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2019
    Co-Authors: Dong Gyu Na, Jung Hwan Baek, Jin Yong Sung
    Abstract:

    BACKGROUND: To retrospectively evaluate the False Negative Rate of ultrasound-guided fine needle aspiration (FNA) according to the nodule size and ultrasound pattern. METHODS: We included 432 consecutive thyroid nodules from 384 patients who underwent ultrasound-guided FNA with benign results (≥1 cm). The False Negative Rate in the nodules was assessed according to the nodule size and ultrasound pattern based on the Korean-Thyroid Imaging Reporting and Data System (K-TIRADS). RESULTS: The overall False Negative Rate was 3.2%. There was a trend toward an increasing False Negative Rate as the K-TIRADS score increased (P < .001). In low or high suspicion nodules (K-TIRADS 3 and 5), there was no significant difference in False Negative Rate according to the nodule size; however, among the intermediate suspicion nodules (K-TIRADS 4), the False Negative Rate was higher in large nodules (≥3 cm, P = .039). CONCLUSION: The impact of nodule size on the False Negative Rate differed according to the ultrasound pattern.

  • False Negative Rate of fine-needle aspiration in thyroid nodules: impact of nodule size and ultrasound pattern.
    Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2019
    Co-Authors: Dong Gyu Na, Jung Hwan Baek, Jin Yong Sung
    Abstract:

    BACKGROUND: To retrospectively evaluate the False Negative Rate of ultrasound-guided fine needle aspiration (FNA) according to the nodule size and ultrasound pattern. METHODS: We included 432 consecutive thyroid nodules from 384 patients who underwent ultrasound-guided FNA with benign results (≥1 cm). The False Negative Rate in the nodules was assessed according to the nodule size and ultrasound pattern based on the Korean-Thyroid Imaging Reporting and Data System (K-TIRADS). RESULTS: The overall False Negative Rate was 3.2%. There was a trend toward an increasing False Negative Rate as the K-TIRADS score increased (P